RCUS
Arcus Biosciences, Inc.
NYSE · Healthcare · Biotechnology · US
$29.66
−1.56%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.6x
Market Cap
$3.78B
MomentumView details →
1D Return
−1.56%
YTD Return
+23.63%
RSI (14)
50.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.6x
Market Cap
$3.78B
RSI (14)
50.2
MomentumView details →
1D Return
−1.56%
YTD Return
+23.63%
SummaryUpdated Jun 1, 2026
Arcus Biosciences, Inc. (NASDAQ:RCUS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Hayward, California. The company went public in March 2018 and focuses on developing innovative cancer immunotherapies targeting the tumor microenvironment. Arcus has built a diverse pipeline of oncology treatments through both internal research and strategic partnerships with major pharmaceutical companies including Gilead Sciences, AstraZeneca, and Taiho Pharmaceutical. The company has advanced multiple drug candidates into late-stage clinical trials, with several programs expected to enter Phase 3 studies by 2025.
Similar companies
Latest newsMore news →
BlackRock Inc. acquired a new stake in Arcus Biosciences, Inc. during the second quarter, purchasing 16,416,249 shares valued at approximately $506.11 million, representing 13.05% ownership.11d agoArcus Biosciences' Compensation Committee granted a new employee options to purchase 2,850 shares of common stock at an exercise price of $28.72 per share.24d ago